Usefulness as the biomarker and effect in the iron metabolism of new splicing variant of hepcidin with liver cancer origin

Research Project

Project/Area Number	15K19302
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Gastroenterology
Research Institution	Asahikawa Medical College
Principal Investigator	Toki Yasumichi 旭川医科大学, 大学病院, 医員 (90596280)
Project Period (FY)	2015-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords	ヘプシジン / スプライシングバリアント / バイオマーカー
Outline of Final Research Achievements	I built the system of measurement to detect hepcidin mRNA and splicing variant of hepcidin mRNA from serum exosome with Digital PCR. Splicing variant of hepcidin mRNA was not detected in healthy person and liver cirrhosis patients without the past of the liver cancer, but it was detected in some liver cirrhosis patients with the past of the liver cancer and liver cancer patients. Splicing variant of hepcidin mRNA was not detected in pancreatic cancer, stomach cancer, and colon cancer patients. From these results, splicing variant of hepcidin mRNA was considered as new useful biomarker in the liver cancer.